Allogene Therapeutics financials
$1.62−0.61%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.6M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $22.0K | $21.0K | $22.0K |
| Gross profit | $4.6M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $22.0K | $21.0K | $22.0K |
| Gross margin | 100.0% | — | — | — | — | — | — | — | — | 100.0% | 100.0% | 100.0% |
| Operating income | -$46.9M | -$46.1M | -$42.4M | -$44.9M | -$56.8M | -$65.2M | -$60.5M | -$71.8M | -$71.4M | -$69.5M | -$85.1M | -$63.0M |
| Net income | -$42.7M | -$42.6M | -$38.8M | -$41.4M | -$50.9M | -$59.7M | -$59.9M | -$66.3M | -$66.4M | -$65.0M | -$85.8M | -$62.3M |
| Net margin | −919.8% | — | — | — | — | — | — | — | — | −295454.5% | −408466.7% | −283122.7% |
| Diluted EPS | $-0.13 | $-0.18 | $-0.17 | $-0.19 | $-0.23 | $-0.28 | $-0.28 | $-0.32 | $-0.35 | $-0.38 | $-0.51 | $-0.37 |
| EBITDA | -$44.3M | -$43.2M | -$39.3M | -$41.8M | -$51.3M | -$62.1M | -$57.3M | -$57.8M | -$62.8M | -$65.9M | -$68.4M | -$59.4M |
| Operating cash flow | -$32.0M | -$12.9M | -$27.6M | -$29.7M | -$39.0M | -$52.9M | -$36.7M | -$44.1M | -$63.6M | -$55.9M | -$53.7M | -$55.5M |
| Free cash flow | -$32.1M | -$12.9M | -$27.6M | -$29.9M | -$39.1M | -$53.0M | -$37.0M | -$44.5M | -$63.6M | -$55.9M | -$53.9M | -$55.5M |
| Diluted shares | 328.9M | 240.3M | 226.2M | 222.0M | 218.9M | 215.4M | 210.9M | 209.2M | 190.0M | 169.1M | 168.7M | 167.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $38.6M | $30.3M | $51.7M | $37.8M | $52.3M | $42.5M |
| Short-term investments | $294.0M | $236.6M | $198.5M | $214.4M | $220.8M | $237.6M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $550.1M | $396.0M | $415.9M | $439.8M | $470.6M | $508.0M |
| Total liabilities | $113.9M | $117.1M | $123.4M | $124.4M | $126.0M | $122.6M |
| Shareholders' equity | $436.2M | $278.9M | $292.5M | $315.3M | $344.6M | $385.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology